Calcitriol in the Treatment of Immunoglobulin A Nephropathy
Status:
Unknown status
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Immunoglobulin A (IgA) nephropathy is the common primary glomerulonephritis in the world.
Much literature suggests that vitamin D and its analogs have profound effects on immune
system function and glomerular mesangial cell proliferation. Therefore, the investigators
plan to conduct a randomized clinical study to evaluate the efficacy of Calcitriol in the
treatment of IgA nephropathy. Forty patients with biopsy-proven IgA nephropathy will be
recruited. They will be randomized to Calcitriol for six months or no treatment. Proteinuria,
renal function, serum and urinary inflammatory markers will be monitored. This study will
explore the potential anti-proteinuric and anti-inflammatory effects of Calcitriol in the
treatment of IgA nephropathy, which has no specific treatment at present.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University First Hospital
Treatments:
Antibodies Calcitriol Immunoglobulin A Immunoglobulins